no updates from PMNIt has been over a month since the company has provided any updates. Not even a tweet since 06 NOV.
I believe the prospectus was published on 16 NOV, but I don't think that was widely marketted.
Hopefully they will get some updated marketing information out soon that provides a vision that is not dependent on aducanumab approval.
I personally do not have confidence in the aducanmab data, but the ban2401 data looks good and fully supports the PMN development approach. Given the massive market size and diversity of patients, I don't see just two drugs (ban2401 and alzheon 801) being sufficient to meet the needs.